Logotype for Eisai Co Ltd

Eisai (4523) investor relations material

Eisai Status Update summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Eisai Co Ltd
Status Update summary11 Sep, 2025

Scientific and clinical background

  • E2086 is a selective orexin receptor 2 agonist developed to address orexin deficiency, the underlying cause of narcolepsy type 1 (NT1), by promoting wakefulness and mitigating cataplexy symptoms in preclinical models.

  • The compound was discovered through high-throughput screening and features a complex, unique chemical structure, with significant improvements in activity achieved through medicinal chemistry and AI-based screening.

  • E2086 is positioned as a once-daily therapy, leveraging expertise in both orexin antagonists and agonists, aiming for broad application in sleep disorders.

  • Preclinical studies showed E2086 has strong efficacy and safety in non-clinical models.

  • Narcolepsy type 1 is characterized by orexin deficiency, leading to high disease burden and unmet medical needs.

Phase 1b clinical trial design and methodology

  • The Phase 1b trial was a multicenter, randomized, double-blind, five-period crossover study in adults with NT1, comparing three doses of E2086 (5, 10, 25 mg), placebo, and modafinil.

  • Each participant received all treatments in a randomized sequence, with washout periods between doses, and efficacy was assessed using the Maintenance of Wakefulness Test (MWT) and Karolinska Sleepiness Scale (KSS).

  • 21 participants (mean age 35.6 years, 42.9% female) were included in the safety analysis; 19 completed all treatments.

Efficacy results

  • E2086 at all tested doses significantly extended sleep latency compared to placebo, with 10 and 25 mg doses outperforming modafinil in maintaining wakefulness up to seven hours post-dose.

  • Subjective sleepiness scores (KSS) also improved significantly with E2086, especially at 10 and 25 mg, which showed greater efficacy than modafinil.

  • E2086 10 mg and 25 mg sustained wakefulness for at least 30 minutes in each MWT trial.

  • All doses of E2086 resulted in statistically significant longer sleep latencies versus placebo (P < 0.0001) and modafinil.

  • At higher doses, patients achieved or exceeded normal wakefulness levels seen in healthy subjects, with sustained effects observed throughout the day.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Eisai earnings date

Logotype for Eisai Co Ltd
Q2 20265 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Eisai earnings date

Logotype for Eisai Co Ltd
Q2 20265 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Eisai Co., Ltd. is a global pharmaceutical company based in Tokyo, Japan. The company focuses on the research and development, manufacturing, and marketing of prescription medicines. Eisai's business activities extend to the discovery, development, manufacture, and sale of pharmaceuticals, including a broad range of therapeutic areas such as neurology and oncology. Eisai is headquartered in Bunkyo-ku, Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage